<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37433988</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-1741</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Nature reviews. Immunology</Title><ISOAbbreviation>Nat Rev Immunol</ISOAbbreviation></Journal><ArticleTitle>The immunology of long COVID.</ArticleTitle><Pagination><StartPage>618</StartPage><EndPage>634</EndPage><MedlinePgn>618-634</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41577-023-00904-7</ELocationID><Abstract><AbstractText>Long COVID is the patient-coined term for the disease entity whereby persistent symptoms ensue in a significant proportion of those who have had COVID-19, whether asymptomatic, mild or severe. Estimated numbers vary but the assumption is that, of all those who had COVID-19 globally, at least 10% have long COVID. The disease burden spans from mild symptoms to profound disability, the scale making this a huge, new health-care challenge. Long COVID will likely be stratified into several more or less discrete entities with potentially distinct pathogenic pathways. The evolving symptom list is extensive, multi-organ, multisystem and relapsing-remitting, including fatigue, breathlessness, neurocognitive effects and dysautonomia. A range of radiological abnormalities in the olfactory bulb, brain, heart, lung and other sites have been observed in individuals with long COVID. Some body sites indicate the presence of microclots; these and other blood markers of hypercoagulation implicate a likely role of endothelial activation and clotting abnormalities. Diverse auto-antibody (AAB) specificities have been found, as yet without a clear consensus or correlation with symptom clusters. There is support for a role of persistent SARS-CoV-2 reservoirs and/or an effect of Epstein-Barr virus reactivation, and evidence from immune subset changes for broad immune perturbation. Thus, the current picture is one of convergence towards a map of an immunopathogenic aetiology of long COVID, though as yet with insufficient data for a mechanistic synthesis or to fully inform therapeutic pathways.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0002-2436-6192</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, London, UK. d.altmann@ic.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whettlock</LastName><ForeName>Emily M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-1094-1897</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Siyi</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0206-9661</Identifier><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arachchillage</LastName><ForeName>Deepa J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0001-5993-4850</Identifier><AffiliationInfo><Affiliation>Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Haematology, Imperial College Healthcare NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyton</LastName><ForeName>Rosemary J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lung Division, Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>LT2-027</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V036939/1</GrantID><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Immunol</MedlineTA><NlmUniqueID>101124169</NlmUniqueID><ISSNLinking>1474-1733</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Nat Rev Immunol. 2023 Oct;23(10):697. doi: 10.1038/s41577-023-00948-9</RefSource><PMID Version="1">37723341</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>12</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId><ArticleId IdType="doi">10.1038/s41577-023-00904-7</ArticleId><ArticleId IdType="pii">10.1038/s41577-023-00904-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carf&#xec;, A., Bernabei, R. &amp; Landi, F. Gemelli against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. J. Am. Med. Assoc. 324, 603&#x2013;605 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding, L. https://www.theguardian.com/world/2020/may/15/weird-hell-professor-advent-calendar-covid-19-symptoms-paul-garner (15 May 2022).</Citation></Reference><Reference><Citation>Simpson, R. &amp; Robinson, L. Rehabilitation after critical illness in people with COVID-19 infection. Am. J. Phys. Med. Rehabil. 99, 470&#x2013;474 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32282359</ArticleId><ArticleId IdType="pmc">7253039</ArticleId><ArticleId IdType="doi">10.1097/PHM.0000000000001443</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard, F. &amp; Perego, E. How and why patients made long COVID. Soc. Sci. Med. 268, 113426 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33199035</ArticleId><ArticleId IdType="pmc">7539940</ArticleId><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId></ArticleIdList></Reference><Reference><Citation>Alwan, N. A. Lessons from long COVID: working with patients to design better research. Nat. Rev. Immunol. 22, 201&#x2013;202 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35169259</ArticleId><ArticleId IdType="pmc">8853146</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00692-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinicci, M. et al. Infection with SARS-CoV-2 variants is associated with different long COVID phenotypes. Viruses 14, 2367 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36366465</ArticleId><ArticleId IdType="pmc">9698829</ArticleId><ArticleId IdType="doi">10.3390/v14112367</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson, K. et al. Post-covid medical complaints following infection with SARS-CoV-2 Omicron vs Delta variants. Nat. Commun. 13, 7363 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36450749</ArticleId><ArticleId IdType="pmc">9709355</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-35240-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli, M., Pujol, J. C., Spector, T. D., Ourselin, S. &amp; Steves, C. J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 399, 2263&#x2013;2264 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35717982</ArticleId><ArticleId IdType="pmc">9212672</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe, B., Xie, Y. &amp; Al-Aly, Z. Acute and posacute sequelae associated with SARS-CoV-2 reinfection. Nat. Med. 28, 2398&#x2013;2405 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36357676</ArticleId><ArticleId IdType="pmc">9671810</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId></ArticleIdList></Reference><Reference><Citation>De Bruijn, S. et al. Lower prevalence of post-COVID-19 condition following Omicron SARS-CoV-2 infection. Preprint at medRxiv https://doi.org/10.1101/2023.04.05.23288157 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.04.05.23288157</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosworth, M. L. et al. Risk of new-onset long covid following reinfection with SARS-CoV-2: community-based cohort study. Preprint at medRxiv https://doi.org/10.1101/2023.04.13.23288522 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.04.13.23288522</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 38, 101019 (2021). There are huge, ongoing efforts to fine-tune the characterization and stratification of long COVID phenotypes, but this effort was seminal in terms of narrating the huge breadth of symptom patterns.</Citation><ArticleIdList><ArticleId IdType="pubmed">34308300</ArticleId><ArticleId IdType="pmc">8280690</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen, M. et al. Characterising long COVID: a living systematic review. BMJ Glob. Health 6, e005427 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34580069</ArticleId><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru, S. &amp; Merad, M. Pathological sequelae of long-haul COVID. Nat. Immunol. 23, 194&#x2013;202 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35105985</ArticleId><ArticleId IdType="pmc">9127978</ArticleId><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso, M. J. &amp; Deeks, S. G. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 43, 268&#x2013;270 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35272932</ArticleId><ArticleId IdType="pmc">8901423</ArticleId><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M. &amp; Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133&#x2013;146 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36639608</ArticleId><ArticleId IdType="pmc">9839201</ArticleId><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Moldofsky, H. &amp; Patcai, J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 11, 37 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21435231</ArticleId><ArticleId IdType="pmc">3071317</ArticleId><ArticleId IdType="doi">10.1186/1471-2377-11-37</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, T. L. &amp; Weitzer, D. J. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) &#x2013; a systemic review and comparison of clinical presentation and symptomatology. Med 57, 418 (2021).</Citation></Reference><Reference><Citation>Choutka, J., Jansari, V., Hornig, M. &amp; Iwasaki, A. Unexplained post-acute infection syndromes. Nat. Med. 28, 911&#x2013;923 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01810-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese, J. T. et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. EBioMedicine 87, 104413 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36563487</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.104413</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit, D. et al. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir. Med. 10, 715&#x2013;724 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35714658</ArticleId><ArticleId IdType="pmc">9197249</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(22)00169-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Altmann, D. M. &amp; Boyton, R. J. Decoding the unknowns in long covid. BMJ 372, n132 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33541867</ArticleId><ArticleId IdType="doi">10.1136/bmj.n132</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B. &amp; Hislop, A. D. The immunology of Epstein-Barr virus-induced disease. Annu. Rev. Immunol. 33, 787&#x2013;821 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25706097</ArticleId><ArticleId IdType="doi">10.1146/annurev-immunol-032414-112326</ArticleId></ArticleIdList></Reference><Reference><Citation>Mina, M. J., Metcalf, C. J., de Swart, R. L., Osterhaus, A. D. &amp; Grenfell, B. T. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 348, 694&#x2013;699 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25954009</ArticleId><ArticleId IdType="pmc">4823017</ArticleId><ArticleId IdType="doi">10.1126/science.aaa3662</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanay, A. Chikungunya virus and autoimmunity. Curr. Opin. Rheumatol. 29, 389&#x2013;393 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28376065</ArticleId><ArticleId IdType="doi">10.1097/BOR.0000000000000396</ArticleId></ArticleIdList></Reference><Reference><Citation>Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200&#x2013;1204 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32555424</ArticleId><ArticleId IdType="doi">10.1038/s41591-020-0965-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Remy-Jardin, M. et al. Assessment of pulmonary arterial circulation 3 months after hospitalization for SARS-CoV-2 pneumonia: Dual-energy CT (DECT) angiographic study in 55 patients. EClinicalMedicine 34, 100778 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33817609</ArticleId><ArticleId IdType="pmc">8008988</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2021.100778</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata, N. et al. Cardiovascular manifestations identified by multi-modality imaging in patients with long COVID. Front. Cardiovasc. Med. 9, 968584 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36211553</ArticleId><ArticleId IdType="pmc">9537639</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2022.968584</ArticleId></ArticleIdList></Reference><Reference><Citation>Joy, G. et al. Prospective case-control study of cardiovascular abnormalities 6 months following mild COVID-19 in healthcare workers. JACC Cardiovasc. Imaging 14, 2155&#x2013;2166 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33975819</ArticleId><ArticleId IdType="pmc">8105493</ArticleId><ArticleId IdType="doi">10.1016/j.jcmg.2021.04.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan, R. T. et al. Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19. Lancet Respir. Med. 9, 107&#x2013;116 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33217366</ArticleId><ArticleId IdType="doi">10.1016/S2213-2600(20)30407-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis, A. et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open 11, e048391 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33785495</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann, V. O. et al. Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nat. Med. 28, 2117&#x2013;2123 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36064600</ArticleId><ArticleId IdType="pmc">9556300</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-02000-0</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xed;ez-Cirarda, M. et al. Multimodal neuroimaging in post-COVID syndrome and correlation with cognition. Brain https://doi.org/10.1093/brain/awac384 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac384</ArticleId></ArticleIdList></Reference><Reference><Citation>Etter, M. M. et al. Severe neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: a prospective cross-sectional study. Nat. Commun. 13, 6777 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36351919</ArticleId><ArticleId IdType="pmc">9645766</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-34068-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud, G. et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 604, 697&#x2013;707 (2022). Not explicitly targeted to report long COVID changes but uses the power of the longitudinal Biobank resource to document CNS imaging changes before and after acute SARS-CoV-2 infection.</Citation><ArticleIdList><ArticleId IdType="pubmed">35255491</ArticleId><ArticleId IdType="pmc">9046077</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Frosolini, A. et al. Magnetic resonance imaging confirmed Olfactory bulb reduction in long COVID-19: literature review and case series. Brain Sci. 12, 430 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35447962</ArticleId><ArticleId IdType="pmc">9029157</ArticleId><ArticleId IdType="doi">10.3390/brainsci12040430</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis, A. et al. Multi-organ impairment and long COVID: a 1-year prospective, longitudinal cohort study. J. R. Soc. Med. 14, 1410768231154703 (2023).</Citation></Reference><Reference><Citation>Gorecka, M. et al. Cardiovascular magnetic resonance imaging and spectroscopy in clinical long-COVID-19 syndrome: a prospective case-control study. J. Cardiovasc. Magn. Reson. 24, 50 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36089591</ArticleId><ArticleId IdType="pmc">9464490</ArticleId><ArticleId IdType="doi">10.1186/s12968-022-00887-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Matheson, A. M. et al. Longitudinal follow-up of postacute COVID-19 syndrome: DL<sub>CO</sub>, quality-of-life and MRI pulmonary gas-exchange abnormalities. Thorax 78, 418&#x2013;421 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36596692</ArticleId><ArticleId IdType="doi">10.1136/thorax-2022-219378</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung, C. C. L. et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut 71, 226&#x2013;229 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34083386</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-324280</ArticleId></ArticleIdList></Reference><Reference><Citation>Leppkes, M. &amp; Neurath, M. F. Rear window-what can the gut tell us about long-COVID? Gastroenterology 163, 376&#x2013;378 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35660031</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2022.05.044</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan, A. et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med 3, 371&#x2013;387.e9 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35434682</ArticleId><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature 591, 639&#x2013;644 (2021). Starting from the clue of progressive BCR somatic hypermutation, this study infers a potential role of persistent SARS-CoV-2 and finds it in gut biopsies.</Citation><ArticleIdList><ArticleId IdType="pubmed">33461210</ArticleId><ArticleId IdType="pmc">8221082</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Y. et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol. Hepatol. 5, 434&#x2013;435 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32199469</ArticleId><ArticleId IdType="pmc">7158584</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30083-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner, A. et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology 163, 495&#x2013;506.e8 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2022.04.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank, Z. et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin. Infect. Dis. 76, e487&#x2013;e490 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36052466</ArticleId><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein, S. R. et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature 612, 758&#x2013;763 (2022). Compelling, comprehensive evidence from post-mortem tissue for persistent SARS-CoV-2 tissue reservoirs.</Citation><ArticleIdList><ArticleId IdType="pubmed">36517603</ArticleId><ArticleId IdType="pmc">9749650</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Su, Y. et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 185, 881&#x2013;895 (2022). A tour-de-force using multi-omic approaches to track patients through acute infection and define correlates of subsequent persistent symptoms.</Citation><ArticleIdList><ArticleId IdType="pubmed">35216672</ArticleId><ArticleId IdType="pmc">8786632</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia, X. et al. Anti-nucleocapsid antibody levels and pulmonary comorbid conditions are linked to post-COVID-19 syndrome. JCI Insight 7, e156713 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35801588</ArticleId><ArticleId IdType="pmc">9310538</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.156713</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Abell&#xe1;n, J. et al. Antibody response to SARS-CoV-2 is associated with long-term clinical outcome in patients with COVID-19: a longitudinal study. J. Clin. Immunol. 41, 1490&#x2013;1501 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34273064</ArticleId><ArticleId IdType="pmc">8285689</ArticleId><ArticleId IdType="doi">10.1007/s10875-021-01083-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso, M. J. et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 36, 109518 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34358460</ArticleId><ArticleId IdType="pmc">8342976</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId></ArticleIdList></Reference><Reference><Citation>Littlefield, K. M. et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequalae of SARS-CoV-2. PLoS Pathog. 18, e1010359 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35617421</ArticleId><ArticleId IdType="pmc">9176759</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1010359</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, K. et al. Long COVID manifests with T cell dysregulation, inflammation, and an uncoordinated adaptive immune response to SARS-CoV-2. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2023.02.09.527892v1 (2023).</Citation></Reference><Reference><Citation>Klein, J. et al. Distinguishing features of Long COVID identified through immune profiling. Preprint at medRxiv https://doi.org/10.1101/2022.08.09.22278592 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pubmed">36597525</ArticleId><ArticleId IdType="pmc">9810233</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold, J. E., Okyay, R. A., Licht, W. E. &amp; Hurley, D. J. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens 10, 763 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34204243</ArticleId><ArticleId IdType="pmc">8233978</ArticleId><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso, M. J. et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Invest. 133, e163669 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36454631</ArticleId><ArticleId IdType="pmc">9888380</ArticleId><ArticleId IdType="doi">10.1172/JCI163669</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubchenko, S., Kril, I., Nadizhko, O., Matsyura, O. &amp; Chopyak, V. Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol. Int. 42, 1523&#x2013;1530 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35650445</ArticleId><ArticleId IdType="pmc">9159383</ArticleId><ArticleId IdType="doi">10.1007/s00296-022-05146-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Mockridge, C. I. et al. Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. Autoimmunity 37, 9&#x2013;15 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15115306</ArticleId><ArticleId IdType="doi">10.1080/08916930310001624656</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Z. X., Zeng, S., Wu, H. X. &amp; Zhou, Y. The risk of systemic lupus erythematosus associated with Epstein-Barr virus infection: a systematic review and meta-analysis. Clin. Exp. Med. 19, 23&#x2013;36 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30361847</ArticleId><ArticleId IdType="doi">10.1007/s10238-018-0535-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375, 296&#x2013;301 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35025605</ArticleId><ArticleId IdType="doi">10.1126/science.abj8222</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloisi, F., Giovannoni, G. &amp; Salvetti, M. Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy. Lancet Neurol. 22, 338&#x2013;349 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36764322</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(22)00471-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds, C. J. et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci. Immunol. 5, eabf3698 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33361161</ArticleId><ArticleId IdType="pmc">8101131</ArticleId><ArticleId IdType="doi">10.1126/sciimmunol.abf3698</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni, A. et al. SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19. Cell Host Microbe 29, 1076&#x2013;1092 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34237248</ArticleId><ArticleId IdType="pmc">8139264</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2021.05.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Captur, G. et al. Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection. EBioMedicine 85, 104293 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36182629</ArticleId><ArticleId IdType="pmc">9515404</ArticleId><ArticleId IdType="doi">10.1016/j.ebiom.2022.104293</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh, C. et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 23, 210&#x2013;216 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf;, C. et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 3, 100663 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35732153</ArticleId><ArticleId IdType="pmc">9214726</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiech, M. et al. Remodeling of T cell dynamics during long COVID is dependent on severity of SARS-CoV-2 infection. Front. Immunol. 13, 886431 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35757700</ArticleId><ArticleId IdType="pmc">9226563</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.886431</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopkins, F. R. et al. Major alterations to monocyte and dendritic cell subsets lasting more than 6 months after hospitalization for COVID-19. Front. Immunol. 13, 1082912 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36685582</ArticleId><ArticleId IdType="pmc">9846644</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.1082912</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank, C. U. et al. Defining &#x2018;T cell exhaustion&#x2019;. Nat. Rev. Immunol. 19, 665&#x2013;674 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31570879</ArticleId><ArticleId IdType="pmc">7286441</ArticleId><ArticleId IdType="doi">10.1038/s41577-019-0221-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks, R. et al. Influenza vaccination reveals sex dimorphic imprints of prior mild COVID-19. Nature https://doi.org/10.1038/s41586-022-05670-5 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05670-5</ArticleId><ArticleId IdType="pubmed">36755095</ArticleId><ArticleId IdType="pmc">10481789</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda, A. et al. Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell 185, 2452&#x2013;2468 (2022). A paper of profound implications, spanning murine and human infection, and offering mechanisms that could square CNS-persistent symptoms with a lack of live virus at the site, including evidence for the role of CCL11.</Citation><ArticleIdList><ArticleId IdType="pubmed">35768006</ArticleId><ArticleId IdType="pmc">9189143</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.06.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda, S. A. et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477, 90&#x2013;94 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21886162</ArticleId><ArticleId IdType="pmc">3170097</ArticleId><ArticleId IdType="doi">10.1038/nature10357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler, J. B., Butuci, M., Wong, A., Kamboj, A. P. &amp; Youngblood, B. A. Mast cell activation is associated with post-acute COVID-19 syndrome. Allergy 77, 1288&#x2013;1291 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34820848</ArticleId><ArticleId IdType="doi">10.1111/all.15188</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32972996</ArticleId><ArticleId IdType="pmc">7857397</ArticleId><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, S. E. et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 12, 5417 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34521836</ArticleId><ArticleId IdType="pmc">8440763</ArticleId><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight, J. S. et al. The intersection of COVID-19 and autoimmunity. J. Clin. Invest. 131, e154886 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34710063</ArticleId><ArticleId IdType="pmc">8670833</ArticleId><ArticleId IdType="doi">10.1172/JCI154886</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, A. K. H. et al. auto-reactive IgM responses are common in critically ill patients, including those with COVID-19. Cell Rep. Med. 2, 100321 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34075365</ArticleId><ArticleId IdType="pmc">8160082</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2021.100321</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283&#x2013;288 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId><ArticleId IdType="doi">10.1038/s41586-021-03631-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, E. et al. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep. Med. 2, 100288 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33969321</ArticleId><ArticleId IdType="pmc">8091032</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2021.100288</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke, C. et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav. Immun. 93, 415&#x2013;419 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33359380</ArticleId><ArticleId IdType="doi">10.1016/j.bbi.2020.12.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Needham, E. J. et al. Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses. Brain 145, 4097&#x2013;4107 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36065116</ArticleId><ArticleId IdType="pmc">9494359</ArticleId><ArticleId IdType="doi">10.1093/brain/awac321</ArticleId></ArticleIdList></Reference><Reference><Citation>Richter, A. G. et al. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clin. Exp. Immunol. 205, 99&#x2013;105 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34082475</ArticleId><ArticleId IdType="pmc">8239842</ArticleId><ArticleId IdType="doi">10.1111/cei.13623</ArticleId></ArticleIdList></Reference><Reference><Citation>Casciola-Rosen, L. et al. IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. JCI Insight 7, e158362 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35349483</ArticleId><ArticleId IdType="pmc">9090251</ArticleId><ArticleId IdType="doi">10.1172/jci.insight.158362</ArticleId></ArticleIdList></Reference><Reference><Citation>Son, K. et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. Eur. Respir. J. 61, 2200970 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36137590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko, N. et al. Loss of Bcl-6-expressing T follicular helper cells and germinal centers in COVID-19. Cell 183, 43&#x2013;157 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff, M. C. et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature 611, 139&#x2013;147 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36044993</ArticleId><ArticleId IdType="pmc">9630115</ArticleId><ArticleId IdType="doi">10.1038/s41586-022-05273-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, Y. et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin. Transl. Sci. 13, 1077&#x2013;1086 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32315487</ArticleId><ArticleId IdType="pmc">7264560</ArticleId><ArticleId IdType="doi">10.1111/cts.12805</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N. Engl. J. Med. 382, e38 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32268022</ArticleId><ArticleId IdType="doi">10.1056/NEJMc2007575</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, Y. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 12, eabd3876 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33139519</ArticleId><ArticleId IdType="pmc">7724273</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, H. et al. Endothelial cell-activating antibodies in COVID-19. Arthritis Rheumatol. 74, 1132&#x2013;1138 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35174669</ArticleId><ArticleId IdType="pmc">9082472</ArticleId><ArticleId IdType="doi">10.1002/art.42094</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat, G. et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J. Transl. Autoimmun. 4, 100100 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33880442</ArticleId><ArticleId IdType="pmc">8049853</ArticleId><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Rehrhmoul, F. et al. Autoimmunity in long COVID and POTS. Oxf. Open Immunol. 4, iqad002 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqad002</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani, M. et al. Autonomic dysfunction in &#x2018;long COVID&#x2019;: rationale, physiology and management strategies. Clin. Med. 21, e63&#x2013;e67 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0896</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, R. et al. Risk of autoimmune disease in patients with COVID-19: a retrospective cohort study. eClinicalMedicine 56, 101783 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36643619</ArticleId><ArticleId IdType="pmc">9830133</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2022.101783</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, C. &amp; Bayry, J. High risk of autoimmune diseases after COVID-19. Nat. Rev. Rheumatol. 12, 1&#x2013;2 (2023).</Citation></Reference><Reference><Citation>Tesch, F. et al. Incident autoimmune diseases in association with a SARS-CoV-2 infection: a matched cohort study. Clin. Rheumatol. https://doi.org/10.1007/s10067-023-06670-0 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.25.23285014</ArticleId><ArticleId IdType="pubmed">37405528</ArticleId><ArticleId IdType="pmc">10497701</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen, N. W. et al. Characterization of autonomic symptom burden in long COVID: a global survey of 2,314 adults. Front. Neurol. 13, 1012668 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36353127</ArticleId><ArticleId IdType="pmc">9639503</ArticleId><ArticleId IdType="doi">10.3389/fneur.2022.1012668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavi, L. Postural tachycardia syndrome and long COVID: an update. Br. J. Gen. Pract. 72, 8&#x2013;9 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34972793</ArticleId><ArticleId IdType="pmc">8714530</ArticleId><ArticleId IdType="doi">10.3399/bjgp22X718037</ArticleId></ArticleIdList></Reference><Reference><Citation>Barizien, N. et al. Clinical characterization of dysautonomia in long COVID-19 patients. Sci. Rep. 11, 14042 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34234251</ArticleId><ArticleId IdType="pmc">8263555</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-93546-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, E., Xie, Y. &amp; Al-Aly, Z. Long-term neurologic outcomes of COVID-19. Nat. Med. 28, 2406&#x2013;2415 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36138154</ArticleId><ArticleId IdType="pmc">9671811</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-02001-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao, J. &amp; Frankland, P. W. COVID fog demystified. Cell 185, 2391&#x2013;2393 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35768007</ArticleId><ArticleId IdType="pmc">9197953</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2022.06.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkataramani, V. &amp; Winkler, F. Cognitive deficits in long COVID-19. N. Engl. J. Med. 387, 1813&#x2013;1815 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36351274</ArticleId><ArticleId IdType="doi">10.1056/NEJMcibr2210069</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga, Z. et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 395, 1417&#x2013;1418 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32325026</ArticleId><ArticleId IdType="pmc">7172722</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan, B. E. et al. COVID-19 associated coagulopathy in critically ill patients: a hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis. J. Thromb. Thrombolysis 51, 663&#x2013;674 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33098540</ArticleId><ArticleId IdType="doi">10.1007/s11239-020-02318-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Jing, H. et al. Pathophysiological mechanisms of thrombosis in acute and long COVID-19. Front. Immunol. 13, 992384 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36466841</ArticleId><ArticleId IdType="pmc">9709252</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.992384</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway, E. M. et al. Understanding COVID-19-associated coagulopathy. Nat. Rev. Immunol. 22, 639&#x2013;649 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35931818</ArticleId><ArticleId IdType="pmc">9362465</ArticleId><ArticleId IdType="doi">10.1038/s41577-022-00762-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Bois, M. C. et al. COVID-19-associated nonocclusive fibrin microthrombi in the heart. Circulation 143, 230&#x2013;243 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33197204</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050754</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty, H. et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost. 19, 2546&#x2013;2553 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34375505</ArticleId><ArticleId IdType="doi">10.1111/jth.15490</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan, N. et al. Impaired exercise capacity in post-COVID-19 syndrome: the role of VWF-ADAMTS13 axis. Blood Adv. 6, 4041&#x2013;4048 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35543533</ArticleId><ArticleId IdType="pmc">9098525</ArticleId><ArticleId IdType="doi">10.1182/bloodadvances.2021006944</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin, M. et al. Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis. J. Thromb. Thrombolysis 18, 490&#x2013;498 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-022-02766-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Patell, R. et al. Post-discharge thrombosis and hemorrhage in patients with COVID-19. Blood 136, 1342&#x2013;1346 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32766883</ArticleId><ArticleId IdType="doi">10.1182/blood.2020007938</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell, D. B., Laubscher, G. J. &amp; Pretorius, E. A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. Biochem. J. 479, 537&#x2013;559 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35195253</ArticleId><ArticleId IdType="doi">10.1042/BCJ20220016</ArticleId></ArticleIdList></Reference><Reference><Citation>Willyard, C. The mystery in micro-clots. Nature 608, 662&#x2013;664 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36002482</ArticleId><ArticleId IdType="doi">10.1038/d41586-022-02286-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu, J. K. et al. SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy. Preprint at bioRxiv https://doi.org/10.1101/2021.10.12.464152 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.12.464152</ArticleId><ArticleId IdType="pubmed">34671772</ArticleId><ArticleId IdType="pmc">8528086</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmenegger, M. et al. Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins. PLoS Pathog. 17, e1010118 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34860860</ArticleId><ArticleId IdType="pmc">8673606</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1010118</ArticleId></ArticleIdList></Reference><Reference><Citation>Berer, K. et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc. Natl Acad. Sci. USA 114, 10719&#x2013;10724 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28893994</ArticleId><ArticleId IdType="pmc">5635914</ArticleId><ArticleId IdType="doi">10.1073/pnas.1711233114</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatanen, T. et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 562, 589&#x2013;594 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30356183</ArticleId><ArticleId IdType="pmc">6296767</ArticleId><ArticleId IdType="doi">10.1038/s41586-018-0620-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaiss, M. M., Joyce, Wu. H. J., Mauro, D., Schett, G. &amp; Ciccia, F. The gut-joint axis in rheumatoid arthritis. Nat. Rev. Rheumatol. 17, 224&#x2013;237 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33674813</ArticleId><ArticleId IdType="doi">10.1038/s41584-021-00585-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer, C. N. et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374, 1632&#x2013;1640 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34941392</ArticleId><ArticleId IdType="pmc">8970537</ArticleId><ArticleId IdType="doi">10.1126/science.aaz7015</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, D., Liwinski, T. &amp; Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492&#x2013;506 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32433595</ArticleId><ArticleId IdType="pmc">7264227</ArticleId><ArticleId IdType="doi">10.1038/s41422-020-0332-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkaid, Y. &amp; Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121&#x2013;141 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24679531</ArticleId><ArticleId IdType="pmc">4056765</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.03.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Q. et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 71, 544&#x2013;552 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35082169</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Q. et al. Multi-kingdom gut microbiota analyses define COVID-19 severity and post-acute COVID-19 syndrome. Nat. Commun. 13, 6806 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36357381</ArticleId><ArticleId IdType="pmc">9648868</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-34535-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Carneiro, V. L., Littlefield, K. M., Watson, R., Palmer, B. E. &amp; Lozupone, C. Inflammation-associated gut microbiome in postacute sequelae of SARS-CoV-2 points towards new therapeutic targets. Gut https://doi.org/10.1136/gutjnl-2022-328757 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2022-328757</ArticleId><ArticleId IdType="pubmed">37666656</ArticleId></ArticleIdList></Reference><Reference><Citation>Vestad, B. et al. Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations. J. Intern. Med. 291, 801&#x2013;812 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35212063</ArticleId><ArticleId IdType="pmc">9115297</ArticleId><ArticleId IdType="doi">10.1111/joim.13458</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosser, E. C. et al. Microbiota-derived metabolites suppress arthritis by amplifying aryl-hydrocarbon receptor activation in regulatory B cells. Cell Metab. 31, 837&#x2013;851 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32213346</ArticleId><ArticleId IdType="pmc">7156916</ArticleId><ArticleId IdType="doi">10.1016/j.cmet.2020.03.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451&#x2013;455 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24226773</ArticleId><ArticleId IdType="pmc">3869884</ArticleId><ArticleId IdType="doi">10.1038/nature12726</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers, E. S. et al. Dietary supplementation with inulin-propionate ester or inulin improves insulin sensitivity in adults with overweight and obesity with distinct effects on the gut microbiota, plasma metabolome and systemic inflammatory responses: a randomised cross-over trial. Gut 68, 1430&#x2013;1438 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30971437</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2019-318424</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo, C. et al. Deficient butyrate-producing capacity in the gut microbiome is associated with bacterial network disturbances and fatigue symptoms in ME/CFS. Cell Host Microbe 31, 288&#x2013;304 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36758522</ArticleId><ArticleId IdType="pmc">10183837</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2023.01.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y., Xu, E., Bowe, B. &amp; Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 28, 583&#x2013;590 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35132265</ArticleId><ArticleId IdType="pmc">8938267</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, E., Xie, Y. &amp; Al-Aly, Z. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. Lancet Diabetes Endocrinol. 11, 120&#x2013;128 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36623520</ArticleId><ArticleId IdType="pmc">9873268</ArticleId><ArticleId IdType="doi">10.1016/S2213-8587(22)00355-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe, B., Xie, Y., Xu, E. &amp; Al-Aly, Z. Kidney outcomes in long COVID. J. Am. Soc. Nephrol. 32, 2851&#x2013;2862 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34470828</ArticleId><ArticleId IdType="pmc">8806085</ArticleId><ArticleId IdType="doi">10.1681/ASN.2021060734</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y. &amp; Al-Aly, Z. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. 10, 311&#x2013;321 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35325624</ArticleId><ArticleId IdType="pmc">8937253</ArticleId><ArticleId IdType="doi">10.1016/S2213-8587(22)00044-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Forshaw, D. et al. STIMULATE-ICP: a pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: a structured protocol. PLoS One 18, e0272472 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36791116</ArticleId><ArticleId IdType="pmc">9931100</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0272472</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Marques, O. et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. Nat. Commun. 13, 1220 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35264564</ArticleId><ArticleId IdType="pmc">8907309</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-28905-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingel, H. et al. Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals. J. Autoimmun. 122, 102682 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34214763</ArticleId><ArticleId IdType="pmc">8214939</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2021.102682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, E. C. Y. et al. High frequency of anti-DSG 2 antibodies in post COVID-19 serum samples. J. Mol. Cell Cardiol. 170, 121&#x2013;123 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35764120</ArticleId><ArticleId IdType="pmc">9233549</ArticleId><ArticleId IdType="doi">10.1016/j.yjmcc.2022.06.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Y. et al. Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection. J. Transl. Med. 19, 524 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34965855</ArticleId><ArticleId IdType="pmc">8716184</ArticleId><ArticleId IdType="doi">10.1186/s12967-021-03184-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Briquez, P. S. et al. Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci. Adv. 8, eabn3777 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36206332</ArticleId><ArticleId IdType="pmc">9544317</ArticleId><ArticleId IdType="doi">10.1126/sciadv.abn3777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund, L. C. et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect. Dis. 21, 1373&#x2013;1382 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33984263</ArticleId><ArticleId IdType="pmc">8110209</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00211-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi, B. et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ 380, e072529 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36631153</ArticleId><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossman J. S. et al. https://www.bmj.com/content/380/bmj-2022-072529/rapid-responses (2023).</Citation></Reference><Reference><Citation>Hastie, C. E. et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat. Commun. 13, 5663 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36224173</ArticleId><ArticleId IdType="pmc">9556711</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-33415-5</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney, L. L. et al. The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine 55, 101762 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36474804</ArticleId><ArticleId IdType="pmc">9714474</ArticleId><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker, M. et al. Persistent COVID-19 symptoms in a community study of 606,434 people in England. Nat. Commun. 13, 1957 (2022). The REACT longitudinal cohort stands as a landmark data set, among other things, clearly demonstrating the kinetics of recovery from acute infection and the long tail of persistence for many over the first year.</Citation><ArticleIdList><ArticleId IdType="pubmed">35413949</ArticleId><ArticleId IdType="pmc">9005552</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-29521-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, E. J. et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat. Commun. 13, 3528 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35764621</ArticleId><ArticleId IdType="pmc">9240035</ArticleId><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators. Estimated global proportions of individuals with persistent fatigue, cognitive and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. J. Am. Med. Assoc. 328, 1604&#x2013;1615 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy, M. J. Circadian rhythm disruption in myalgic encephalomyelitis/chronic fatigue syndrome: implications for the post-acute sequelae of COVID-19. Brain Behav. Immun. Health 20, 100412 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35465246</ArticleId><ArticleId IdType="pmc">9019698</ArticleId><ArticleId IdType="doi">10.1016/j.bbih.2022.100412</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus, P. et al. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine 33, 6173&#x2013;6177 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26475444</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2015.10.018</ArticleId></ArticleIdList></Reference><Reference><Citation>Apostolou, E. et al. Saliva antibody-fingerprint of reactivated latent viruses after mild/asymptomatic COVID-19 is unique in patients with myalgic-encephalomyelitis/chronic fatigue syndrome. Front. Immunol. 13, 949787 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36341457</ArticleId><ArticleId IdType="pmc">9630598</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2022.949787</ArticleId></ArticleIdList></Reference><Reference><Citation>Montoya, J. G. et al. Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proc. Natl Acad. Sci. USA 114, E7150&#x2013;E7158 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28760971</ArticleId><ArticleId IdType="pmc">5576836</ArticleId><ArticleId IdType="doi">10.1073/pnas.1710519114</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff, A. L. Inflammation correlates with symptoms in chronic fatigue syndrome. Proc. Natl Acad. Sci. USA 114, 8914&#x2013;8916 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28811366</ArticleId><ArticleId IdType="pmc">5576849</ArticleId><ArticleId IdType="doi">10.1073/pnas.1712475114</ArticleId></ArticleIdList></Reference><Reference><Citation>Fevang, B. et al. Lasting immunological imprint of primary Epstein-Barr virus infection with associations to chronic low-grade inflammation and fatigue. Front. Immunol. 12, 715102 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34987499</ArticleId><ArticleId IdType="pmc">8721200</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.715102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam, M. H. et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch. Intern. Med. 169, 2142&#x2013;2147 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">20008700</ArticleId><ArticleId IdType="doi">10.1001/archinternmed.2009.384</ArticleId></ArticleIdList></Reference><Reference><Citation>Patcai, J. Is &#x2018;Long COVID&#x2019; similar to &#x2018;Long SARS&#x2019;? Oxf. Open. Immunol. 3, 1&#x2013;5 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfimm/iqac002</ArticleId></ArticleIdList></Reference><Reference><Citation>Satterfield, B. A., Bhatt, D. L. &amp; Gersh, B. J. Cardiac involvement in the long-term implications of COVID-19. Nat. Rev. Cardiol. 19, 332&#x2013;341 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34686843</ArticleId><ArticleId IdType="doi">10.1038/s41569-021-00631-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Finlay, J. B. et al. Persistent post-COVID-19 smell loss is associated with immune cell infiltration and altered gene expression in olfactory epithelium. Sci. Transl. Med. 14, eadd0484 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36542694</ArticleId><ArticleId IdType="pmc">10317309</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.add0484</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly, Z., Bowe, B. &amp; Xie, Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat. Med. 28, 1461&#x2013;1467 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35614233</ArticleId><ArticleId IdType="pmc">9307472</ArticleId><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli, M. et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect. Dis. 22, 43&#x2013;55 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34480857</ArticleId><ArticleId IdType="pmc">8409907</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(21)00460-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet, M., Dercon, Q. &amp; Harrison, P. J. Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections. Brain Behav. Immun. 103, 154&#x2013;162 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35447302</ArticleId><ArticleId IdType="pmc">9013695</ArticleId><ArticleId IdType="doi">10.1016/j.bbi.2022.04.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivan, M., Greenhalgh, T., Milne, R. &amp; Delaney, B. Are vaccines a potential treatment for long covid? BMJ 377, o988 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35584848</ArticleId><ArticleId IdType="doi">10.1136/bmj.o988</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani, D. et al. Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ 377, e069676 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35584816</ArticleId><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida, T. et al. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with long COVID. J. Med. Virol. 94, 3416&#x2013;3420 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35238053</ArticleId><ArticleId IdType="pmc">9088489</ArticleId><ArticleId IdType="doi">10.1002/jmv.27689</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran, V. T. et al. Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the ComPaRe e-Cohort in France. BMJ Med. 2, e000229 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36910458</ArticleId><ArticleId IdType="pmc">9978748</ArticleId><ArticleId IdType="doi">10.1136/bmjmed-2022-000229</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain, W. D. et al. The impact of COVID vaccination on symptoms of long COVID: an international survey of people with lived experience of long COVID. Vaccines 10, 652 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35632408</ArticleId><ArticleId IdType="pmc">9146071</ArticleId><ArticleId IdType="doi">10.3390/vaccines10050652</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg, E. et al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): a prospective cohort study. Vaccine 40, 4424&#x2013;4431 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35725782</ArticleId><ArticleId IdType="pmc">9170535</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.090</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>